Elephants and cancer

Elephants rarely get cancer due to a combination of factors, including multiple copies of the p53 gene and a unique form of programmed cell death. These adaptations help them eliminate damaged cells more effectively, reducing the risk of cancerous mutations.

Here's a more detailed explanation:

Multiple Copies of p53:
The p53 gene is crucial for preventing cancer by repairing damaged DNA or triggering cell death in damaged cells. Elephants have about 40 copies of this gene, compared to the two copies humans have. These extra copies significantly enhance their ability to detect and eliminate cells with DNA damage, thus preventing tumor formation.

Apoptosis:
Elephants also exhibit a higher rate of apoptosis (programmed cell death) in response to DNA damage. When their cells detect damage, they are more likely to self-destruct, preventing the spread of potentially cancerous cells.

Peto's Paradox:
The fact that elephants, despite their large size and long lifespan, have a low cancer rate is known as Peto's paradox. This paradox highlights how some species have evolved unique mechanisms to mitigate the increased cancer risk associated with large body size and cell count.

Evolutionary Adaptations:
Elephants' evolutionary history has favored the development of these cancer-fighting mechanisms, potentially as a response to the challenges of maintaining a large body size and long lifespan.

Essentially, elephants have evolved a robust system of cellular surveillance and self-destruction that effectively protects them from developing cancer at a rate comparable to other species.

ChatGPT